Innovative Bispecific Nanobody Targeting ERBB2 and FCGR3A for Advanced Breast Cancer Therapy
VHH-P319 is a humanized nanobody-based biologic in the biological testing stage, designed to target erb-b2 receptor tyrosine kinase 2 (ERBB2) and Fc gamma receptor IIIa (FCGR3A). This novel fusion construct offers a promising therapeutic strategy for breast cancer by simultaneously engaging two clinically relevant targets. By effectively addressing ERBB2 and FCGR3A, VHH-P319 represents a next-generation approach in immuno-oncology, with potential advantages in efficacy and selectivity. The development of VHH-P319 exemplifies the innovation in nanobody therapeutics for the treatment of major cancer types such as breast cancer, supporting unmet needs in the field.
| Candidate | VHH-P319 |
| Target | erb-b2 receptor tyrosine kinase 2 (ERBB2) Fc gamma receptor IIIa (FCGR3A) |
| Modality | humanized bispecific VHH |
| Indication | Breast Cancer |
Licensing Opportunity
VHH-P319 is available for out-licensing and collaboration. We invite industry partners to engage in discussions to accelerate the clinical and commercial development of this innovative breast cancer therapeutic.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P319 |
Modality
VHH-P319 is engineered as a homodimeric, bispecific antibody fusion construct, integrating the antigen-binding capacity of an anti-ERBB2 IgG1 monoclonal antibody with a nanobody variable heavy chain against CD16A (FCGR3A), connected by a flexible (G4S)3 linker and expressed in Chinese hamster ovary (CHO) cells. The structural features of nanobodies confer small molecular size, high stability, and deep tumor penetration. These attributes enable VHH-P319 to effectively infiltrate tumor tissues, potentially enhance immune cell engagement, and maintain pharmacological activity in the tumor microenvironment, offering distinct advantages for the treatment of breast cancer over conventional monoclonal antibodies.
Target
ERBB2 and FCGR3A are critical molecular targets in oncology. ERBB2, a member of the receptor tyrosine kinase family, mediates cell growth and differentiation and is frequently overexpressed in certain subtypes of breast cancer, leading to aggressive tumor behavior. FCGR3A, expressed primarily on natural killer (NK) cells and some macrophages, is vital for antibody-dependent cell-mediated cytotoxicity. The co-targeting of ERBB2 and FCGR3A enables VHH-P319 to block oncogenic signaling via ERBB2 and recruit immune effector functions through FCGR3A. In breast cancer, ERBB2 overexpression is a proven therapeutic target, while FCGR3A engagement amplifies anti-tumor immunological responses. Thus, dual targeting with VHH-P319 leverages the proven efficacy of ERBB2 inhibition and the strategic immune activation via FCGR3A, supporting a differentiated and compelling therapeutic approach.
Mechanism of Action
VHH-P319 exerts its therapeutic action by bispecifically binding to ERBB2 on tumor cells and FCGR3A (CD16A) on immune effector cells. This dual engagement disrupts oncogenic ERBB2-driven signal transduction while simultaneously bridging tumor cells with FCGR3A-expressing natural killer cells, thereby facilitating antibody-dependent cellular cytotoxicity and augmenting anti-tumor immune responses. The nanobody format, with its modular design and small size, provides a versatile platform that can be further developed into advanced therapeutic formats such as bispecifics or antibody-drug conjugates. This approach enables the simultaneous modulation of tumor and immune cell function, enhancing clinical potential in breast cancer and supporting future applications in combination regimens or for additional indications.
Breast Cancer
Breast cancer represents one of the most prevalent malignancies globally, affecting a significant proportion of women and a smaller subset of men. The disease spectrum encompasses various molecular subtypes, with ERBB2-positive breast cancers known for their aggressive progression but responsiveness to targeted therapies. Standard treatment modalities include surgery, radiation, chemotherapy, hormone therapy, and targeted agents against specific pathways. Despite advances, current treatments face limitations such as the emergence of resistance, off-target toxicities, and inadequate response in certain patient populations. There remains a high unmet need for innovative therapies capable of improving clinical outcomes, particularly in advanced or treatment-resistant cases. VHH-P319, by precisely targeting both ERBB2 and FCGR3A, offers the prospect of overcoming resistance mechanisms and enhancing immune-mediated tumor eradication. This novel bispecific nanobody holds significant promise for addressing unmet medical needs in breast cancer management, representing a strategic addition to the evolving landscape of targeted oncology therapeutics.